---
title: "Lysergide (DT120) in Generalized anxiety disorder: Effect on quality measures"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Effect on quality measures. Topics: Anxiety Response at 6 Months (MBHR2) and Use of Anxiety Severity Measure (MBHR1): Merit-based Incentive Payment System registry measures and Use of High-Risk Medications in Older Adults: benzodiazepine rate and the severe generalized anxiety disorder exception. 2 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Effect on quality measures

<a id="heading-2.1.2.13"></a>

## 2.1.2.13 Effect of Lysergide on Quality Measures

<a id="topic-2.1.2.13-1"></a>

### Anxiety Response at 6 Months (MBHR2) and Use of Anxiety Severity Measure (MBHR1): Merit-based Incentive Payment System registry measures

> “Use of Anxiety Severity Measure (MBHR1)”
> “Measures the percentage of adult patients (18+) with an anxiety disorder diagnosis who complete a standardized anxiety severity tool such as the GAD-7 or BAI during the measurement period.”
> “Anxiety Response at 6 Months (MBHR2)”
> “Evaluates treatment response for adults (18+) with anxiety disorders by measuring symptom improvement over time, defined as a 25% or greater reduction in GAD-7 score at 6 months (+/– 60 days) following an index visit with a positive severity score.”

Source: [Healthmonix 2026 Mental and Behavioral Health Registry announcement (2026)](https://healthmonix.com/2026/02/05/2026-mental-and-behavioral-health-registry-mbhr/)

> “The APA Mental and Behavioral Health Registry (MBHR) was again approved by the Centers for Medicare and Medicaid Services (CMS) to participate in the Merit-Based Incentive Payment System (MIPS) for 2026 as a Qualified Clinical Data Registry (QCDR).”

Source: [American Psychological Association Mental and Behavioral Health Registry measures page (2026)](https://www.apaservices.org/practice/reimbursement/health-registry/measures)

<a id="topic-2.1.2.13-2"></a>

### Use of High-Risk Medications in Older Adults: benzodiazepine rate and the severe generalized anxiety disorder exception

> “Patients with two or more benzodiazepine prescriptions ordered on different days, and who did not have a diagnosis of seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, or severe generalized anxiety disorder on or between January 1 of the year prior to the measurement period and the IPSD for benzodiazepines.”

Source: [CMS Use of High-Risk Medications in Older Adults eCQM flow (2025)](https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS156-v14.0.000-eCQM-Flow.pdf)

> “The percentage of persons 67 years of age and older who had at least two dispensing events for the same high-risk medication.”
> “The DDE and DAE measures are based on recommendations in the American Geriatrics Society (AGS) 2023 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults”

Source: [NCQA Use of High-Risk Medications in Older Adults measure description](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/use-of-high-risk-medications-in-older-adults-dae/)

<a id="topic-2.1.2.13-3"></a>

### Lysergide-specific effect on quality measures

No evidence found.

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
